Learn More about Lumida ETF
Powered by LumidaWealth.com
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
No Result
View All Result
  • Lumida Wealth
  • Lumida Ledger
  • LUMIDA ETF
  • About Us
Home Lifestyle Health and Longevity

How Much Muscle Should You Have — and What Happens When You Lose It?

by Team Lumida
April 14, 2026
in Health and Longevity
Reading Time: 3 mins read
A A
0
diagram

Photo by julien Tromeur on Unsplash

Share on TelegramShare on TwitterShare on FacebookShare on LinkedinShare on Whatsapp
  • Skeletal muscle makes up roughly 40% of total body weight on average — but there are no official guidelines on how much you should have, and the data varies significantly by age, sex, and ethnicity
  • After age 40, adults lose up to 8% of muscle mass per decade in a process called sarcopenia — linked to increased risk of falls, diabetes, heart disease, and early mortality
  • Accurate measurement requires expensive tools like MRI, DEXA scans, or CT imaging — consumer-grade methods like bioimpedance scales and calipers are useful approximations but can vary widely
  • Two strength training sessions per week targeting all major muscle groups — combined with a protein-rich diet (10-35% of daily calories) — is the evidence-backed baseline for preserving and building muscle

What Happened?

Muscle mass — specifically skeletal muscle, which controls physical movement and posture — makes up roughly 40% of total body weight in the average adult. A foundational 2000 study of 468 adults found that skeletal muscle percentage declines with age across both sexes: men ages 18-35 average 40-44%, dropping below 31% after 76; women average 31-33% at peak, declining below 26% by their late seventies. Despite its importance, there are no official recommended guidelines on target muscle mass percentages. Clinicians typically rely on body composition assessments — measuring fat versus lean mass — as a practical proxy, since isolating muscle mass alone requires imaging technology not available in routine care.

Why It Matters?

Low skeletal muscle mass is not a cosmetic concern — it is a clinical risk factor. Sarcopenia, the age-related loss of muscle mass and function, is associated with diabetes, heart disease, chronic liver and kidney disease, osteoporosis, surgical complications, and significantly elevated mortality risk. The financial implications are also substantial: sarcopenia-related hospitalizations, falls, and functional decline cost the U.S. healthcare system tens of billions annually. Emerging research also suggests a link between higher muscle mass and cognitive and psychological health, though more evidence is needed. Meanwhile, different measurement tools — D-creatinine dilution vs. MRI, for example — can produce results that diverge by up to 13 kg for the same patient, complicating clinical decision-making.

What’s Next?

The evidence-backed prescription is straightforward: two or more strength training sessions per week, targeting all major muscle groups, combined with adequate protein intake (10-35% of daily calories from high-quality sources including meat, fish, eggs, beans, and nuts). For older adults, maintaining muscle mass is increasingly recognized as one of the most powerful levers for extending healthspan — not just lifespan. As population aging accelerates globally, expect muscle preservation to move from the gym floor to the center of preventive medicine, with insurers and health systems developing structured sarcopenia screening and intervention programs in the years ahead.

Source: Healthline

Previous Post

Saudi Arabia Tells Washington: Drop the Hormuz Blockade Before Iran Opens a Second Front

Next Post

Bessent: Trump’s Tariff Wall Could Be Fully Rebuilt by July — and Rates Should Fall

Recommended For You

The FDA Is Fast-Tracking Psychedelics. The Infrastructure to Support Them Isn’t Ready.

by Team Lumida
7 minutes ago
Abstract colorful psychedelic swirling patterns

Trump's executive order to accelerate psychedelic drug development is welcome — but Bloomberg Opinion's Lisa Jarvis warns the ketamine clinic free-for-all is a cautionary tale the FDA must...

Read more

Ultrasound on a Chip: Butterfly Network’s $4,000 Device Is Taking Medical Imaging Global

by Team Lumida
3 days ago
a person holding a tablet

Butterfly Network's semiconductor-based handheld ultrasound costs a fraction of traditional machines and has reached 150,000 deployments worldwide, pairing AI with imaging to put diagnostics in the hands of...

Read more

Nearly 1 in 8 Americans Now Uses Sleep Aids — and Pharma Is Taking Notice

by Team Lumida
5 days ago
woman sleeping on bed under blankets

A new federal study finds 13% of U.S. adults rely on prescription drugs, OTC supplements, marijuana, or CBD to sleep, as Eli Lilly's $7.8B acquisition of a sleep...

Read more

Amazon One Medical Launches GLP-1 Weight Loss Program at $25 a Month

by Team Lumida
6 days ago
Amazon Targets Rural America: A Game-Changer for Delivery Services

Amazon One Medical is rolling out a weight management program that includes GLP-1 medications, offering compounded pills starting at $25/month with same-day delivery in 3,000 cities.

Read more

Melatonin: What Mayo Clinic Says About Its Side Effects, Safety, and Best Uses

by Team Lumida
3 weeks ago
Melatonin: What Mayo Clinic Says About Its Side Effects, Safety, and Best Uses

Melatonin is generally safe for short-term use and non-habit-forming, but it carries real side effects and drug interactions that most users overlook — Mayo Clinic breaks down what...

Read more

AI Scribes Save Clinicians 13–16 Minutes a Day — and Boost Visit Volume by 1.7%, Study Finds

by Team Lumida
3 weeks ago
AI Investment Boom: How Tech Giants Are Leading the Charge

The largest study of AI scribe adoption to date — 8,500+ clinicians across five academic medical centers — found the tools cut EHR time by 3% and documentation...

Read more

America’s Fertility Rate Just Hit a Record Low — and the Numbers Are Getting Harder to Ignore

by Team Lumida
3 weeks ago
America’s Fertility Rate Just Hit a Record Low — and the Numbers Are Getting Harder to Ignore

The U.S. general fertility rate fell to 53.1 births per 1,000 women in 2025 — a record low — while the total fertility rate dropped to 1.57, well...

Read more

Healthcare Roundup: Medicare Advantage Gets a $13B Boost, Drug Tariffs Hit 100%, and Wegovy Goes Discount

by Team Lumida
4 weeks ago
person sitting while using laptop computer and green stethoscope near

A packed week in healthcare: Medicare Advantage rates came in at a better-than-expected 2.48% increase, Trump unveiled 100% tariffs on some brand-name drugs, Gilead and Neurocrine spent $8B...

Read more

Why Americans Pay More for Healthcare Than Anyone Else in the World

by Team Lumida
4 weeks ago
doctor holding red stethoscope

A new WSJ analysis breaks down the structural forces behind America's sky-high healthcare costs — from monopoly hospitals and unregulated drug prices to administrative bloat and physician salaries...

Read more

Genetic Tests Come Under Federal Scrutiny as Trump Administration Targets Lab Fraud

by Team Lumida
4 weeks ago
Supreme Court Signals It Will Strike Down Trump’s Birthright Citizenship Order

The CMS has opened a public comment period on how to curb fraudulent genetic testing billing — a billion-dollar problem involving unnecessary tests marketed directly to consumers and...

Read more
Next Post
US Treasury Secretary Bessent: Terming Out US Debt Is “A Long Way Off”

Bessent: Trump's Tariff Wall Could Be Fully Rebuilt by July — and Rates Should Fall

Pentagon–Anthropic Feud Escalates as AI Policy Clash Threatens Defense Contracts

Investors Are Valuing Anthropic at $800 Billion — More Than Double Its February Price

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Related News

Trump Tariffs Leave Key Questions on China Supply Chain Rules Unanswered

Trump Leans on Foreign Policy Wins as Domestic Pressures Mount

October 31, 2025
blue and yellow striped country flag

Zelenskiy Loses Key Adviser Amid Corruption Probe as US Pressure Intensifies on Ukraine Peace Deal

November 29, 2025
man sitting on gang chair with feet on luggage looking at airplane

US Faces $12.5 Billion Tourism Revenue Loss in 2025 Amid International Travel Slump

May 13, 2025

Subscribe to Lumida Ledger

Browse by Category

  • Lifestyle
    • Family Office
    • Health and Longevity
    • Next Gen Wealth
    • Trust, Tax, and Estate
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Latest
    • Macro
    • Markets
    • Real Estate
  • Research
    • Trackers
  • Themes
    • Aging & Longevity
    • AI
    • Biotech
    • CRE
    • Cybersecurity
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
    • Software
Facebook Twitter Instagram Youtube TikTok LinkedIn
Lumida News

Premium insights to help you invest beyond the ordinary. Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser

CATEGORIES

  • Aging & Longevity
  • AI
  • Alt Assets
  • Biotech
  • CRE
  • Crypto
  • Cybersecurity
  • Digital Assets
  • Equities
  • Family Office
  • Health and Longevity
  • Latest
  • Legacy Brands
  • Lifestyle
  • Macro
  • Markets
  • News
  • Next Gen Wealth
  • Nuclear Renaissance
  • Private Credit
  • Real Estate
  • Software
  • Themes
  • Trackers
  • Trust, Tax, and Estate

BROWSE BY TAG

AI AI chips AI demand Amazon Apple Artificial Intelligence Banking Bitcoin China Commercial Real Estate CPI Crypto Donald Trump EARNINGS ELON MUSK ETF Ethereum Federal Reserve financial services generative AI Goldman Sachs Google India Inflation Interest Rates Investment Strategy Japan Jerome Powell JPMorgan Markets Meta Microsoft Nasdaq Nvidia OpenAI private equity S&P 500 SEC Semiconductor stock market Tech Stocks tesla Trump Wells Fargo Whale Watch

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018

No Result
View All Result
  • Home
  • Earnings
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018